Publications by authors named "M Bersanelli"

The management of patients with advanced melanoma is becoming more complex than in past years, due to the recent innovations in the therapeutic scenario. New treatment options, such as the immunotherapeutic combination of ipilimumab and nivolumab, and new BRAF and MEK inhibitors recently introduced, namely encorafenib and binimetinib, were recently approved by the Italian regulatory entities, enriching the systemic therapy armamentarium. In this context, tailoring the therapeutic strategy basing on the patient's characteristics is even more crucial to improve the clinical outcome.

View Article and Find Full Text PDF

Background: The treatment of heavily pretreated patients with metastatic renal cell carcinoma (mRCC) represents an unmet medical need and is still challenging.

Objectives: The primary objective was to assess the effectiveness of the lenvatinib plus everolimus combination and the secondary objective was the toxicity profile of this combination.

Design: We conducted a longitudinal retrospective study examining mRCC patients pre-treated with one or more lines of therapy among different cancer centers in Italy.

View Article and Find Full Text PDF

Background: Peritoneal metastases (PM) have been reported in approximately 1% of patients with metastatic Renal Cell Carcinoma (mRCC). Outcome data are limited due to the rarity of this metastatic site. Therefore, the aim of our study is to describe renal cell carcinoma (RCC) patients with PM treated as per clinical practice.

View Article and Find Full Text PDF
Article Synopsis
  • Immune-related liver injury (irLI) occurs more frequently in patients with hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs) compared to those with other solid tumors, showing an incidence of 11.4% versus 2.6%.
  • Patients with HCC experienced irLI earlier (median of 1.4 months) than those with other cancers (median of 4.7 months), but had higher rates of irLI resolution (72.1% vs. 58.3%).
  • The study suggests that while irLI leads to improved overall survival in HCC patients with milder cases, it also results in lower need for corticosteroids, indicating a different response pattern compared to
View Article and Find Full Text PDF
Article Synopsis
  • - Geriatric patients aged 80 and older are often excluded from clinical trials for immune checkpoint inhibitors (ICIs), despite their potential different responses due to unique biological factors.
  • - A study analyzed data from 885 patients treated with ICIs, finding that those aged 80 and above with low levels of inflammatory markers (NLR and SII) exhibited significantly better treatment responses and longer survival outcomes.
  • - The research suggests that lower inflammatory levels before starting ICI treatment can be a useful predictor for improved effectiveness and survival rates in older cancer patients.
View Article and Find Full Text PDF